

IN THE U.S. PATENT AND TRADEMARK OFFICE

In re application of

Jose COURTY et al.

Conf.

Application No. NEW NATIONAL PHASE

Group

Filed May 2, 2005

Examiner

PEPTIDE FRAGMENTS OF THE HARP FACTOR INHIBITING ANGIOGENESIS

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION CONCURRENT WITH THE
FILING OF A NEW PATENT APPLICATION)

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

May 2, 2005

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, and in fulfillment of the duty of disclosure under 37 C.F.R. § 1.56, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- ☐ Copies of the U.S. patents or publications are not submitted since the USPTO has waived their submission for applications filed after June 30, 2003.
- ☐ Submitted herewith is a legible copy of (i) each foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- ☒ This application is a National Phase of a PCT application. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should have been forwarded from the International Search Authority pursuant to the trilateral agreement between the USPTO, EPO and JPO, or they are U.S. patents or U.S. published applications. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)

JC14 Rec'd CT/PTO 02 MAY 2005

a. ☐ **DOCUMENTS IN THE ENGLISH LANGUAGE**

The attached non U.S. patents, non U.S. patent application publications, foreign publications, or other information in the English language do not require a statement of relevancy.

b. ☐ **DOCUMENTS NOT IN THE ENGLISH LANGUAGE**

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ☒ **FOREIGN SEARCH REPORT OR ACTION**

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(A)(3).

d. ☐ **OTHER**

The following additional information is provided for the Examiner's consideration.


FEES

This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

If The Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned.

Respectfully submitted,

YOUNG & THOMPSON


Philip Dubois, Reg. No. 50,696
745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297
Telefax (703) 685-0573
(703) 979-4709

PD/yr

Enclosures: ☒ Form PTO-1449(s)
☐ Documents
☒ Foreign Search Report
☐ Other: _____

(Use several sheets if necessary)

Application No.: 53342
NEW NATIONAL PHASE

Filing Date:
May 2, 2005

Group Art Unit:

[illegible][illegible]

	HAMPTON B S ET AL.; "Structural and functional characterization of full-length heparin-binding growth associated molecule.", MOLECULAR BIOLOGY OF THE CELL, (1992 JAN) 3 (1) 85-93. XP009029422, figure 2
	BERNARD-PIERROT ISABELLE ET AL.; "Dominant negative effectors of heparin affin regulatory peptide (HARP) angiogenic and transforming activities.", JOURNAL OF BIOLOGICAL CHEMISTRY, (2002 AUG 30) 277 (35) 32071-7., XP002245580
	PAPADIMITRIOU E ET AL.; "HARP induces angiogenesis in vivo and in vitro: implication of N or C terminal peptides." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (2001 MAR 23) (1) 306-13., XP002245581
	PAPADIMITRIOU E ET AL.; "Endothelial cell proliferation induced by HARP: Implication of N or C terminal peptides.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 274, no. 1, 21 July 2000 (2000-07-21), pages 242-248, XP002245582, ISSN: 0006-291X

DATE CONSIDERED

* English language abstract provided for the Examiner's convenience